MABTENANCE: International, Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation Alone in Patients With Chronic Lymphocytic Leukemia.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 29 Nov 2017
At a glance
- Drugs Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms MABTENANCE
- 23 Nov 2017 Planned End Date changed from 1 Dec 2017 to 1 Feb 2018.
- 23 Nov 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Feb 2018.
- 10 Jun 2017 Biomarkers information updated